Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate

Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate

Bibliographic Details
Main Authors:	Clerico, M, Faggiano, F, Palace, J, Rice, G, Tintore, M, Durelli, L
Format:	Conference item
Published:	2005

Similar Items

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
by: Clerico, M, et al.
Published: (2008)

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
by: Clerico, M, et al.
Published: (2008)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
by: Clerico, M, et al.
Published: (2006)

Early treatment to prevent conversion of clinically isolated syndrome to clinically defined multiple sclerosis: a Cochrane metanalysis
by: Clerico, M, et al.
Published: (2008)

Conversion from clinically isolated syndromes to multiple sclerosis: how could we prevent it? A Cochrane review of published trials
by: Clerico, M, et al.
Published: (2007)

Immunomodulatory treatments for preventing conversion from clinically isolated syndromes to multiple sclerosis: a Cochrane review on their efficacy
by: Clerico, M, et al.
Published: (2007)

Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis
by: Clerico, M, et al.
Published: (2008)

A Cochrane review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to multiple sclerosis
by: Clerico, M, et al.
Published: (2006)

To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
by: Clerico, M, et al.
Published: (2009)

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
by: Valéria Coelho Santa Rita Pereira, et al.
Published: (2012-10-01)

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
by: GJ Melendez-Torres, et al.
Published: (2017-09-01)

A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis
by: E.J. Ramos González, et al.
Published: (2021-05-01)

The best indication to early treat the clinically isolated syndrome based on the clinical onset. A Cochrane analysis
by: Clerico, M, et al.
Published: (2009)

CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
by: Andrew F Tyler, et al.
Published: (2013-01-01)

Manifestation of Susac syndrome during interferon beta-1a and glatiramer acetate treatment for misdiagnosed multiple sclerosis: a case report
by: Joanna Roskal-Wałek, et al.
Published: (2021-09-01)

The role of glatiramer acetate in the early treatment of multiple sclerosis
by: David W Brandes
Published: (2010-06-01)

New features of glatiramer acetate for the treatment of remitting multiple sclerosis
by: N. Y. Lasch
Published: (2015-12-01)

Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages
by: G. J. Melendez-Torres, et al.
Published: (2018-10-01)

Pharmacoeconomic assessment of the effectiveness of glatiramer acetate (Copaxone®) in patients with multiple sclerosis
by: G. Ya. Shvarts
Published: (2005-06-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
by: Massimiliano Mirabella, et al.
Published: (2022-04-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
by: Oscar Fernández
Published: (2012-08-01)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
by: Mikhail Melnikov, et al.
Published: (2020-01-01)

Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
by: Niklas Bergvall, et al.
Published: (2014-01-01)

Nicolau syndrome following glatiramer acetate for multiple sclerosis: Case and review of reports
by: Methma Udawatta, et al.
Published: (2024-04-01)

Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients
by: María José Zarzuelo-Romero, et al.
Published: (2021-10-01)

Drug-Induced Liver Injury by Glatiramer Acetate Used for Treatment of Multiple Sclerosis
by: Attila Onmez, et al.
Published: (2013-12-01)

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
by: Aaron Boster, et al.
Published: (2011-09-01)

A case of Disseminated Herpes Zoster in a patient with Multiple Sclerosis on Glatiramer acetate
by: C. Halasan, et al.
Published: (2020-01-01)

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis
by: P Tappenden, et al.
Published: (2004-06-01)

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
by: Anne Waschbisch, et al.
Published: (2011-01-01)

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis
by: Genaro Gabriel Ortíz, et al.
Published: (2022-06-01)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
by: Arielle Kasindi, et al.
Published: (2022-05-01)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
by: Arthur Komlosh, et al.
Published: (2019-07-01)

Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura
by: Iftach Sagy, et al.
Published: (2016-04-01)

Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate
by: Ioana S. Barac, et al.
Published: (2023-06-01)

MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
by: Ignacio Casanova, et al.
Published: (2023-10-01)

GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
by: T. E. Shmidt
Published: (2016-12-01)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
by: Justin M. Honce, et al.
Published: (2020-09-01)